Standout Papers
- VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents (2003)
- Immunological considerations for COVID-19 vaccine strategies (2020)
- Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus (2000)
- Going viral with cancer immunotherapy (2014)
Immediate Impact
7 by Nobel laureates 25 from Science/Nature 59 standout
Citing Papers
Understanding and targeting resistance mechanisms in cancer
2023 Standout
Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity
2023 Standout
Works of Brian D. Lichty being referenced
Endogenous T cells prevent tumor immune escape following adoptive T cell therapy
2019
Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy
2018
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Brian D. Lichty | 4014 | 2312 | 2310 | 2859 | 97 | 7.2k | |
| Thomas W. Dubensky | 1304 | 4734 | 2711 | 2025 | 98 | 7.7k | |
| Janet W. Hartley | 5184 | 4113 | 4097 | 1759 | 171 | 11.7k | |
| Dmitry M. Shayakhmetov | 3558 | 1481 | 3306 | 1833 | 75 | 5.9k | |
| Karen Mossman | 1711 | 3796 | 2378 | 1381 | 152 | 8.4k | |
| Jonathan L. Bramson | 1748 | 3200 | 2102 | 2351 | 173 | 6.6k | |
| Narendra Chirmule | 3795 | 1998 | 4064 | 1255 | 114 | 7.6k | |
| Raymond V. Gilden | 2735 | 2300 | 2231 | 992 | 193 | 7.0k | |
| Nicola La Monica | 1326 | 1371 | 2323 | 659 | 103 | 5.5k | |
| Dennis Panicali | 1761 | 4519 | 1965 | 1940 | 83 | 8.3k | |
| Michael J. Imperiale | 2617 | 597 | 3420 | 2819 | 153 | 7.0k |
All Works
Login with ORCID to disown or claim papers
Loading papers...